newsfilter
← Latest News
GlobeNewswire·

Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026

AMIX
  • Autonomix Medical presented its microchip-enabled sensing platform at the 2026 TCT Annual Scientific Conference to advance precision nerve-targeted treatments.
  • The company focuses on renal denervation as a primary near-term application while developing a standalone sensing system for signal acquisition, mapping, & real-time catheter positioning.
  • Autonomix aims to create a "GPS" for nerve procedures to provide physicians with direct measurements of neural activity during blood pressure regulation treatments.
  • The investigational catheter utilizes a custom antenna array & proprietary microchip to amplify & digitize low-amplitude signals near the detection point to reduce degradation.
  • Early preclinical studies in healthy swine successfully recorded electrical signals around the renal, celiac, & common hepatic arteries before & after ablation.
  • The company targets incorporating expanded capabilities into a commercial offering by the end of 2028, subject to successful development, financing, & regulatory authorization.
  • Initial regulatory clearance is planned for a standalone sensing system without claims for renal denervation guidance or treatment verification.
  • Autonomix operates on a "Sense. Treat. Verify." approach to map electrical activity, support targeted intervention, & assess post-treatment changes.
  • The technology remains investigational & has not been cleared or approved for marketing in any jurisdiction.
Company
Autonomix Medical, Inc.
Keywords
Nasdaq:AMIX, Autonomix Medical, Inc., Autonomix Medical, Inc., NASDAQ: AMIX, medical device company, nerve-targeted treatments, TCT 2026, Nervous System, nervous system